109 related articles for article (PubMed ID: 26750924)
21. Copper Tolerance and Characterization of a Copper-Responsive Operon, copYAZ, in an M1T1 Clinical Strain of Streptococcus pyogenes.
Young CA; Gordon LD; Fang Z; Holder RC; Reid SD
J Bacteriol; 2015 Aug; 197(15):2580-92. PubMed ID: 26013489
[TBL] [Abstract][Full Text] [Related]
22. An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae.
Champney WS; Mentens N; Zurawick K
Curr Microbiol; 2004 Oct; 49(4):239-47. PubMed ID: 15386111
[TBL] [Abstract][Full Text] [Related]
23. Novel Drug Targets for Food-Borne Pathogen Campylobacter jejuni: An Integrated Subtractive Genomics and Comparative Metabolic Pathway Study.
Mehla K; Ramana J
OMICS; 2015 Jul; 19(7):393-406. PubMed ID: 26061459
[TBL] [Abstract][Full Text] [Related]
24. Mycoplasma genitalium: a comparative genomics study of metabolic pathways for the identification of drug and vaccine targets.
Butt AM; Tahir S; Nasrullah I; Idrees M; Lu J; Tong Y
Infect Genet Evol; 2012 Jan; 12(1):53-62. PubMed ID: 22057004
[TBL] [Abstract][Full Text] [Related]
25. PolC-type polymerase III of Streptococcus pyogenes and its use in screening for chemical inhibitors.
Yang F; Dicker IB; Kurilla MG; Pompliano DL
Anal Biochem; 2002 May; 304(1):110-6. PubMed ID: 11969194
[TBL] [Abstract][Full Text] [Related]
26. Computational screening of potential drug targets for pathogens causing bacterial pneumonia.
Nayak S; Pradhan D; Singh H; Reddy MS
Microb Pathog; 2019 May; 130():271-282. PubMed ID: 30914386
[TBL] [Abstract][Full Text] [Related]
27. Identification of druggable targets for Acinetobacter baumannii via subtractive genomics and plausible inhibitors for MurA and MurB.
Kaur N; Khokhar M; Jain V; Bharatam PV; Sandhir R; Tewari R
Appl Biochem Biotechnol; 2013 Sep; 171(2):417-36. PubMed ID: 23846799
[TBL] [Abstract][Full Text] [Related]
28. In silico modeling of the type 2 IDI enzymes of Bacillus licheniformis, Pseudomonas stutzeri, Streptococcus pyogenes, and Staphylococcus aureus for virtual screening of potential inhibitors of this therapeutic target.
Torktaz I; Shahbani Zahiri H; Akbari Noghabi K
J Mol Graph Model; 2013 Feb; 39():176-82. PubMed ID: 23280415
[TBL] [Abstract][Full Text] [Related]
29. mef(A), mef(E) and a new mef allele in macrolide-resistant Streptococcus spp. isolates from Norway.
Sangvik M; Littauer P; Simonsen GS; Sundsfjord A; Dahl KH
J Antimicrob Chemother; 2005 Nov; 56(5):841-6. PubMed ID: 16172106
[TBL] [Abstract][Full Text] [Related]
30. Identification and characterization of potential drug targets by subtractive genome analyses of methicillin resistant Staphylococcus aureus.
Uddin R; Saeed K
Comput Biol Chem; 2014 Feb; 48():55-63. PubMed ID: 24361957
[TBL] [Abstract][Full Text] [Related]
31. Genome-scale reconstruction of the Streptococcus pyogenes M49 metabolic network reveals growth requirements and indicates potential drug targets.
Levering J; Fiedler T; Sieg A; van Grinsven KW; Hering S; Veith N; Olivier BG; Klett L; Hugenholtz J; Teusink B; Kreikemeyer B; Kummer U
J Biotechnol; 2016 Aug; 232():25-37. PubMed ID: 26970054
[TBL] [Abstract][Full Text] [Related]
32. The antibacterial activity of peptides derived from human beta-2 glycoprotein I is inhibited by protein H and M1 protein from Streptococcus pyogenes.
Nilsson M; Wasylik S; Mörgelin M; Olin AI; Meijers JC; Derksen RH; de Groot PG; Herwald H
Mol Microbiol; 2008 Feb; 67(3):482-92. PubMed ID: 18093092
[TBL] [Abstract][Full Text] [Related]
33. RNA sequencing uncovers antisense RNAs and novel small RNAs in Streptococcus pyogenes.
Le Rhun A; Beer YY; Reimegård J; Chylinski K; Charpentier E
RNA Biol; 2016; 13(2):177-95. PubMed ID: 26580233
[TBL] [Abstract][Full Text] [Related]
34. A novel bacterial resistance mechanism against human group IIA-secreted phospholipase A2: role of Streptococcus pyogenes sortase A.
Movert E; Wu Y; Lambeau G; Touqui L; Areschoug T
J Immunol; 2011 Dec; 187(12):6437-46. PubMed ID: 22075700
[TBL] [Abstract][Full Text] [Related]
35. Increase in fluoroquinolone non-susceptibility among clinical Streptococcus pyogenes in Belgium during 2007-10.
Van Heirstraeten L; Leten G; Lammens C; Goossens H; Malhotra-Kumar S
J Antimicrob Chemother; 2012 Nov; 67(11):2602-5. PubMed ID: 22815354
[TBL] [Abstract][Full Text] [Related]
36. Emergence of fluoroquinolone-resistant Streptococcus pyogenes in Japan by a point mutation leading to a new amino acid substitution.
Arai K; Hirakata Y; Yano H; Kanamori H; Endo S; Hirotani A; Abe Y; Nagasawa M; Kitagawa M; Aoyagi T; Hatta M; Yamada M; Nishimaki K; Takayama Y; Yamamoto N; Kunishima H; Kaku M
J Antimicrob Chemother; 2011 Mar; 66(3):494-8. PubMed ID: 21172783
[TBL] [Abstract][Full Text] [Related]
37. Treponema pallidum putative novel drug target identification and validation: rethinking syphilis therapeutics with plant-derived terpenoids.
Dwivedi UN; Tiwari S; Singh P; Singh S; Awasthi M; Pandey VP
OMICS; 2015 Feb; 19(2):104-14. PubMed ID: 25683888
[TBL] [Abstract][Full Text] [Related]
38. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
39. Pathway analysis of Acinetobacter baylyi: a combined bioinformatic and genomics approach.
Singh S; Joshi P; Chopade BA
Chem Biol Drug Des; 2011 Nov; 78(5):893-905. PubMed ID: 21777392
[TBL] [Abstract][Full Text] [Related]
40. Intrinsic reduced susceptibility of serotype 6 Streptococcus pyogenes to fluoroquinolone antibiotics.
Orscheln RC; Johnson DR; Olson SM; Presti RM; Martin JM; Kaplan EL; Storch GA
J Infect Dis; 2005 Apr; 191(8):1272-9. PubMed ID: 15776373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
